EMA Targets Inconsistent Cardiovascular Toxicity Assessments In Oncology Trials

 
• By Eliza Slawther
  
The EMA is proposing tailored guidelines that will assess the cardiovascular safety of cancer drugs (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Safety

More from Pink Sheet